<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425865</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2015-05</org_study_id>
    <nct_id>NCT02425865</nct_id>
  </id_info>
  <brief_title>Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET</brief_title>
  <acronym>In-TARGET</acronym>
  <official_title>Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PHASE: IV

      TYPE OF STUDY: With direct benefit

      DESCRIPTIVE: multicenter, open-label, uncontrolled trial

      INCLUSION CRITERIA: Adults with moderate to severe ulcerative colitis who failed
      corticosteroids and immunosupressive therapy, or are intolerant to immunosuppressors. All
      included patients will be naïve to anti-TNF therapy. Active disease at golimumab treatment
      initiation defined as a MAYO score ≥6 and with an endoscopic sub score ≥2.

      OBJECTIVE: To determine the proportion of patients with Continuous Clinical Response (CCR)
      and endoscopic remission after one year of golumimab at week 54.

      STUDY DESIGN:

      Induction Phase :

      Week 0: golimumab 200mg- Week 2: golimumab 100 mg- Week 6: golimumab 50 mg

      Maintenance Phase I : Week 10-Week 54 Week 10-Week 54 • Patients with primary clinical
      response*: Standard regimen with golimumab 50 mg Q4W (or 100 mg Q4W if &gt; 80 kg)

        -  Patients without primary clinical response at week 10 or with flare between week 10-week
           54*: Optimization to 100 mg Q4W (or combination therapy with azathioprine if &gt; 80 kg or
           switch from azathioprine to methotrexate if already on azathioprine at golimumab
           initiation or patient with known intolerance to thiopurines)

        -  Early escape at Week 18: Primary non-responders who are still not responding at week 18
           to dose optimization at Weeks 10 and 14 will be considered treatment failures and will
           be followed up (call or visit) at week 54 for safety.

             -  Clinical response is defined as a decrease from baseline in the Mayo score ≥30% and
                ≥3 points, accompanied by either a rectal bleeding sub score of 0 or 1 or a
                decrease from baseline in the rectal bleeding sub score ≥1

      Intermittent Phase II : Week 54-Week 108

      • Patients with CCR and MH at week 54 and on golimumab 50 mg every 4 weeks: Stop golimumab
      and continuation of thiopurines or methotrexate if on combination therapy

      • Patients with CCR and MH at week 54 and on golimumab 100 mg every 4 weeks: De-escalation to
      50 mg every 4 weeks and continuation of thiopurines or methotrexate if on combination therapy

      • Restart/Escalate golimumab on flare (defined in section 4 of the protocol) to the phase I
      dose; 50 mg q4wk or 100mg q4wk (similar to the phase I regimen)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NUMBER OF PATIENTS: 200 patients

      INCLUSION PERIOD: 33 months

      STUDY DURATION: 57 months

      MAIN EVALUATION Primary endpoints

      • Week 10-54: proportion of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at
      week 54

      Data base lock, data analysis and display (publication) will happen when all included
      subjects have completed the 108-week visit.

      SECONDARY EVALUATION

      For all included patients:

        -  Phase II (week 54-108): proportion of patients in CCR with MH (endoscopic Mayo score of
           0 or 1) at week 108, after discontinuation or dose de-escalation (from 100 to 50 mg) of
           golimumab treatment at year 1 in the subgroup of patients in CCR and with MH (endoscopic
           Mayo score of 0 or 1) at week 54

        -  Factors associated with treatment success (see primary endpoint)

        -  Efficacy of dose optimization in patients who loose response between week 10 and 54

        -  Clinical remission at week 54 • Clinical remission at week 108 • Partial MAYO score at
           week 54 and 108 • PRO2 (Partial Mayo minus PGA) at week 54 and 108 • CCR between study
           inclusion and week 54 and 108 • Steroid-free clinical remission at week 54 and 108 • MH
           (endoscopic score MAYO 0-1) at week 54 and 108 • Changes in faecal calprotectin levels
           from baseline to week 54 and 108 • Colectomy between W0 and W54 and 108

        -  UC-related hospitalizations throughout the trial • Histological remission9 at W54 and
           108

        -  PRO: Fatigue (FACIT), disability (IBD Disability index), QoL (SHS-IBD VAS)

        -  PK data (golimumab trough levels and antibodies against golimumab)

        -  Proportion of late responders being in Clinical Response from week 18 to week 54 and
           with MH at week 54 following treatment intensification in Maintenance Phase

      For the subgroup of patients who are primary non-responders to golimumab at week 10, we will
      assess the efficacy of treatment optimization, including the percentage of patients achieving
      continuous clinical response and endoscopic remission at one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Clinical Response and Endoscopic Remission</measure>
    <time_frame>Week 54</time_frame>
    <description>proportion of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at week 54</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous Clinical Response and Endoscopic Remission after discontinuation or de- escalation of golimumab</measure>
    <time_frame>Week 108</time_frame>
    <description>proportion of patients maintaining continuous clinical response and endoscopic remission at week 108, after discontinuation or de-escalation of golimumab treatment at year 1 in the subgroup of patients in continuous clinical response (CCR) and with mucosal healing (endoscopic Mayo score of 0 or 1) at week 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of dose optimization in patients who loose response between week 10 and 54</measure>
    <time_frame>Week 54</time_frame>
    <description>proportion of patients maintaining continuous clinical response after dose optimization in patients who loose response between week 10 and 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission at week 54</measure>
    <time_frame>week 54</time_frame>
    <description>proportion of patient with clinical remission (partial Mayo score) at week 54</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission at week 108</measure>
    <time_frame>week 108</time_frame>
    <description>proportion of patient with clinical remission (partial mayo score) at week 108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO2 (Partial Mayo minus PGA) at week 54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>Evolution of PRO2 (Partial Mayo minus PGA) at week 54 and 108 according the clinical and endoscopic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCR between study inclusion and week 54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>proportion of patient with CCR at week 54 and 108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free clinical remission at week 54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>proportion of patient with steroid-free clinical remission at week 54 and 108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MH (endoscopic score MAYO 0-1) at week 54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>proportion of patient with MH (endoscopic score MAYO 0-1) at week 54 and 108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in faecal calprotectin levels from baseline at week 54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>Evolution of faecal calprotectin levels from baseline at week 54 and 108 according the clinical and endoscopic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy between W0 and W54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>Proportion of patient with colectomy between W0 and W54 and W108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC-related hospitalizations throughout the trial</measure>
    <time_frame>week 108</time_frame>
    <description>Proportion of patient with UC-related hospitalizations throughout the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological remission at W54 and 108</measure>
    <time_frame>week 108</time_frame>
    <description>Proportion of patient with histological remission at W54 and W108</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO: Fatigue (FACIT), disability (IBD Disability index), QoL (SHS-IBD VAS)</measure>
    <time_frame>week 108</time_frame>
    <description>Evolution of PRO: Fatigue (FACIT), disability (IBD Disability index), QoL (SHS-IBD VAS) according the clinical and endoscopic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK data (golimumab trough levels and antibodies against golimumab)</measure>
    <time_frame>week 108</time_frame>
    <description>Evolution of PK (golimumab trough levels and antibodies against golimumab) according the clinical and endoscopic remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late responders being in Clinical Response from week 18 to week 54 and with MH at week 54 following treatment intensification in Maintenance Phase</measure>
    <time_frame>week 108</time_frame>
    <description>Proportion of late responders being in Clinical Response from week 18 to week 54 and with MH at week 54 following treatment intensification in Maintenance Phase</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ULCERATIVE COLITIS</condition>
  <arm_group>
    <arm_group_label>open-label, uncontrolled trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if &gt; 80 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GOLIMUMAB</intervention_name>
    <description>Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse</description>
    <arm_group_label>open-label, uncontrolled trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Age sup 18 years and inf 75 years

          -  Established diagnosis of UC for at least 3 months (pancolitis, left-sided colitis,
             proctosigmoiditis and or proctitis are allowed).

          -  Adults with moderately-to-severely active UC who had an inadequate response to or
             failed to tolerate steroids AND thiopurines (azathioprine or 6-mercaptopurine) or
             adults with moderately-to-severely active UC who had no response to an adequate
             steroid course and starting golimumab.

          -  Active disease at golimumab treatment initiation defined as a partial MAYO score
             sup/equal 6 with an endoscopic sub score sup/equal 2.

          -  Patients concurrently treated with oral corticosteroids will receive a stable dose
             (prednisone 20 ≤mg/day for at least 2 weeks) before baseline.

          -  Patient has to be treated with oral 5-ASA at time of inclusion regardless of the dose
             if no contra-indication. If the patient is not on oral 5-ASA during the screening
             period, he/she should start mesalamine at 2g per day or asacol at 1.6 g per day, in
             the absence of contra-indication.

          -  Patients are allowed stable dose of thiopurines (azathioprine or 6-mercaptopurine
             stable dose for at least 4 weeks).

          -  Naïve to anti-TNF therapy, and other biologics, including anti-integrin antibodies and
             for all biologics known to be effective for UC (approved or investigational).

          -  Naïve to JAK inhibitors (approved or investigational)

          -  A contraceptive method during the whole study for childbearing potential female
             patients.

        EXCLUSION CRITERIA

          -  Age under 18 and over 75.

          -  People unable to give their consent (because of their physical or mental state).

          -  Absence of written consent.

          -  Pregnancy or breastfeeding.

          -  Patients with severe acute colitis or patients at imminent risk for colectomy.

          -  History of colectomy.

          -  History of colonic mucosal dysplasia or adenomatous colonic polyps that are not
             removed.

          -  Screening stool study positive for enteric pathogens or Clostridium difficile toxin.

          -  Oral corticosteroids at a dose &gt; 20 mg prednisone or its equivalent per day.

          -  Any current or previous use of cyclosporine, tacrolimus, anti-TNF therapy, and other
             biologics, including anti-integrin antibodies (approved or investigational), JAK
             inhibitors (approved or investigational), or any current or previous use of an
             investigational agent within 5 half-lives of that agent before the first study agent
             injection.

          -  Contraindication to anti-TNF therapy according to drug labelling:

               -  Active infection.

               -  Non-treated latent tuberculosis.

               -  Heart failure (NYHA: Grade III and IV).

               -  Malignancy during the previous 5 years.

               -  Demyelinating neurological disease.

               -  Should be vaccinated with attenuated live vaccines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Peyrin Biroulet, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucine Vuitton, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Louis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascaline Rabiéga, PhD</last_name>
    <email>prabiega@getaid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Mailhat, PhD</last_name>
    <email>projet@getaid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU LIEGE - Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard LOUIS, MD,PhD</last_name>
      <phone>+32436667889</phone>
      <email>Edouard.Louis@ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie WERTZ</last_name>
      <phone>+32 4 366 74 39</phone>
      <email>swertz@chu.ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>EDOUARD LOUIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathurin FUMERY</last_name>
      <email>fumery.mathurin@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Mathurin FUMERY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAPHAELLE BLONBET</last_name>
    </contact>
    <contact_backup>
      <email>rblondet@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LUCINE VUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen Unversity Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>STEPHANIE VIENNOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony BUISSON</last_name>
      <email>a-buisson@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anthony BUISSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital BEAUJON</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <email>yoram.bouhnik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>YORAM BOUHNIK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Colmar- Hopital Trousseau Medecine A</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURIANNE PLASTARAS, MD</last_name>
      <email>laurianne.plastaras@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>LAURIANNE PLASTARAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin PARIENTE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin PARIENTE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier- Hopital saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLAUME PINTON DE CHAMBRUHN</last_name>
      <email>gpinetondechambrun@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>PIERRE BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUILLAUME PINTON DE CHAMBRUHN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ROMAIN ALTWEGG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANTES - Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELISE KERDREUX</last_name>
      <email>Elise.KERDREUX@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>ARNAUD BOURREILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MATHURIN FLAMANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAROLINE TRANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de NICE- Hopital Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEROME FILLIPI, MD</last_name>
      <email>filippi.j@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>JEROME FILLIPI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XAVIER HEBUTERNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NADIA ARAB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes- Hopital Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUDOVIC CAILLO, MD</last_name>
      <email>Ludovic.CAILLO@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>LUDOVIC CAILLO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hopital BICHAT</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANNE-LAURE PELLETIER, MD</last_name>
      <email>anne-laure.pelletier@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>ANNE-LAURE PELLETIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux- Hopital Haut Levèque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID LAHARIE, MD</last_name>
    </contact>
    <contact_backup>
      <email>david.laharie@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>DAVID LAHARIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>FLORIAN POULLENOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU LYON- Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEPHANE NANCEY, MD</last_name>
      <email>stephane.nancey@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>STEPHANE NANCEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CADIOT, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume CADIOT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU RENNES - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
    </contact>
    <contact_backup>
      <email>guillaume.bouguen@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GUILLAUME BOUGUEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIE DEWITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne- Hopital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XAVIER ROBLIN, MD</last_name>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>XAVIER ROBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>EMILIE DEL TEDESCO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard DUCLOS, MD,PhD</last_name>
      <phone>+33388127442</phone>
      <email>bduclos@noos.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard DUCLOS, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JEAN MARIE REIMUND, MDPHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SANDRA OREMPULLER</last_name>
      <email>orempuller.s@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>JACQUES MOREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CYRIELLE GILLETTA DE SAINT JOSEPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OLIVIER TESTON, ARC</last_name>
    </contact>
    <investigator>
      <last_name>LAURENCE PICON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hopital Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURENT PEYRIN BIROULET, MD,PhD</last_name>
      <phone>+33383153354</phone>
      <email>peyrinbiroulet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laurent PEYRIN-BIROULET, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille ZALLOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UC, IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

